Robert Weinberg, Leroy Hood, Bob Löwenberg, Olli Kallioniemi, Rene Bernards, Guido Kroemer, Hans Clevers, Matthias Uhlen ...
read more »
WIN Consortium Receives 3 Million Euro EU FP7 Grant to Conduct WINTHER, WIN’s First Cancer Personalized Medicine Clinica ...
read more »
WIN2014 Symposium June 23-24, First Announcement: “WINning Combinations for Precision Cancer Medicine”
read more »



Subscribe to our newsletter:


"The WIN Consortium offers an opportunity to make an impact on personalized cancer therapy across the globe by increasing the number of patients having access to innovative clinical trials and treatment with the latest innovative drugs."

  - Dr. John Mendelsohn, Chairman

"New ways of learning are needed" as personalised medicine enters routine practice, says WIN Consortium Scientific Advisory Board Chair Richard L. Schilsky

Prospective observational registries, which record every clinical encounter with every patient, are going to be the way to continue progress in our understanding of cancer, according to Richard L Schilsky, Chair of the WIN Consortium Scientific Advisory Board and Chief Medical Officer of the American Society of Clinical Oncology (ASCO).

Genetic characterisation has led to cancers which were traditionally considered common becoming instead a collection of rare diseases. It means that there are now too many cancers, too many drugs in development and not enough patients, time or money to study everything by doing clinical trials, he says.

In the October 2013 EJC News Focus, Dr. Schilsky tells Helen Saul that as personalised medicine enters the clinic, changes are needed – and are happening – in research, development and the regulation of new cancer drugs.